STOCK TITAN

[Form 4] USANA Health Sciences Inc Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

USANA Health Sciences (USNA) Form 4: Chief Sales Officer David Mulham disclosed a direct sale of company stock.

  • Transaction date: 30 Jul 2025
  • Shares sold: 3,515 common shares
  • Sale price: $30.26 per share (approx. $106 k total proceeds)
  • Shares owned after sale: 9,260 (direct)

No derivative securities were reported. The filing was signed on 31 Jul 2025.

USANA Health Sciences (USNA) Modulo 4: Il Chief Sales Officer David Mulham ha comunicato una vendita diretta di azioni della società.

  • Data della transazione: 30 lug 2025
  • Azioni vendute: 3.515 azioni ordinarie
  • Prezzo di vendita: 30,26 $ per azione (circa 106.000 $ di proventi totali)
  • Azioni possedute dopo la vendita: 9.260 (dirette)

Non sono stati segnalati titoli derivati. Il modulo è stato firmato il 31 lug 2025.

USANA Health Sciences (USNA) Formulario 4: El Director de Ventas, David Mulham, declaró una venta directa de acciones de la empresa.

  • Fecha de la transacción: 30 jul 2025
  • Acciones vendidas: 3,515 acciones ordinarias
  • Precio de venta: 30,26 $ por acción (aproximadamente 106,000 $ en ingresos totales)
  • Acciones poseídas después de la venta: 9,260 (directas)

No se reportaron valores derivados. El formulario fue firmado el 31 jul 2025.

USANA Health Sciences (USNA) Form 4: 최고 영업 책임자 데이비드 멀햄이 회사 주식 직접 매도를 공시했습니다.

  • 거래 날짜: 2025년 7월 30일
  • 매도 주식 수: 보통주 3,515주
  • 매도 가격: 주당 30.26달러 (총 약 106,000달러 수익)
  • 매도 후 보유 주식: 9,260주 (직접 보유)

파생 증권은 보고되지 않았습니다. 서류는 2025년 7월 31일에 서명되었습니다.

USANA Health Sciences (USNA) Formulaire 4 : Le directeur commercial David Mulham a déclaré une vente directe d'actions de la société.

  • Date de la transaction : 30 juil. 2025
  • Actions vendues : 3 515 actions ordinaires
  • Prix de vente : 30,26 $ par action (environ 106 000 $ de produit total)
  • Actions détenues après la vente : 9 260 (directes)

Aucun titre dérivé n’a été déclaré. Le document a été signé le 31 juil. 2025.

USANA Health Sciences (USNA) Formular 4: Chief Sales Officer David Mulham meldete einen direkten Verkauf von Unternehmensaktien.

  • Transaktionsdatum: 30. Juli 2025
  • Verkaufte Aktien: 3.515 Stammaktien
  • Verkaufspreis: 30,26 $ pro Aktie (ca. 106.000 $ Gesamterlös)
  • Aktienbesitz nach Verkauf: 9.260 (direkt)

Keine Derivate wurden gemeldet. Die Einreichung wurde am 31. Juli 2025 unterschrieben.

Positive
  • None.
Negative
  • Chief Sales Officer sold 3,515 shares, reducing personal stake by roughly 27%, which can be interpreted as a modestly negative insider signal.

Insights

TL;DR: Insider sells ~28% of holdings; mildly negative sentiment, limited fundamental impact.

The CSO’s 3,515-share sale reduces his direct stake to 9,260 shares, indicating a roughly 27% trim of his prior position. While insider selling can signal reduced confidence, the dollar value (~$106k) is modest relative to USNA’s market cap and trading volume. No accompanying 10b5-1 plan is noted, so timing appears discretionary. Investors may view the move as a minor negative, but the limited size suggests minimal effect on liquidity or control.

USANA Health Sciences (USNA) Modulo 4: Il Chief Sales Officer David Mulham ha comunicato una vendita diretta di azioni della società.

  • Data della transazione: 30 lug 2025
  • Azioni vendute: 3.515 azioni ordinarie
  • Prezzo di vendita: 30,26 $ per azione (circa 106.000 $ di proventi totali)
  • Azioni possedute dopo la vendita: 9.260 (dirette)

Non sono stati segnalati titoli derivati. Il modulo è stato firmato il 31 lug 2025.

USANA Health Sciences (USNA) Formulario 4: El Director de Ventas, David Mulham, declaró una venta directa de acciones de la empresa.

  • Fecha de la transacción: 30 jul 2025
  • Acciones vendidas: 3,515 acciones ordinarias
  • Precio de venta: 30,26 $ por acción (aproximadamente 106,000 $ en ingresos totales)
  • Acciones poseídas después de la venta: 9,260 (directas)

No se reportaron valores derivados. El formulario fue firmado el 31 jul 2025.

USANA Health Sciences (USNA) Form 4: 최고 영업 책임자 데이비드 멀햄이 회사 주식 직접 매도를 공시했습니다.

  • 거래 날짜: 2025년 7월 30일
  • 매도 주식 수: 보통주 3,515주
  • 매도 가격: 주당 30.26달러 (총 약 106,000달러 수익)
  • 매도 후 보유 주식: 9,260주 (직접 보유)

파생 증권은 보고되지 않았습니다. 서류는 2025년 7월 31일에 서명되었습니다.

USANA Health Sciences (USNA) Formulaire 4 : Le directeur commercial David Mulham a déclaré une vente directe d'actions de la société.

  • Date de la transaction : 30 juil. 2025
  • Actions vendues : 3 515 actions ordinaires
  • Prix de vente : 30,26 $ par action (environ 106 000 $ de produit total)
  • Actions détenues après la vente : 9 260 (directes)

Aucun titre dérivé n’a été déclaré. Le document a été signé le 31 juil. 2025.

USANA Health Sciences (USNA) Formular 4: Chief Sales Officer David Mulham meldete einen direkten Verkauf von Unternehmensaktien.

  • Transaktionsdatum: 30. Juli 2025
  • Verkaufte Aktien: 3.515 Stammaktien
  • Verkaufspreis: 30,26 $ pro Aktie (ca. 106.000 $ Gesamterlös)
  • Aktienbesitz nach Verkauf: 9.260 (direkt)

Keine Derivate wurden gemeldet. Die Einreichung wurde am 31. Juli 2025 unterschrieben.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Mulham David Mulham

(Last) (First) (Middle)
3838 WEST PARKWAY BLVD

(Street)
SALT LAKE CITY UT 84120

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
USANA HEALTH SCIENCES INC [ USNA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CHIEF SALES OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
07/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/30/2025 S 3,515 D $30.26 9,260 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
Remarks:
/s/ Joshua Foukas, Attorney-in-Fact 07/31/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did USNA report on this Form 4?

Chief Sales Officer David Mulham sold 3,515 common shares on 30 Jul 2025 at $30.26 each.

How many USNA shares does the CSO now own?

After the sale, he holds 9,260 direct shares.

What was the total value of the shares sold?

Proceeds were about $106,000 (3,515 shares × $30.26).

Were any derivative securities involved in this filing?

No; Table II shows no derivative transactions.

When was the Form 4 signed and filed?

It was signed on 31 Jul 2025 and reflects the 30 Jul 2025 transaction.
Usana Health Sciences Inc

NYSE:USNA

USNA Rankings

USNA Latest News

USNA Latest SEC Filings

USNA Stock Data

549.75M
10.76M
42.19%
59.03%
4.45%
Packaged Foods
Medicinal Chemicals & Botanical Products
Link
United States
SALT LAKE CITY